Navigation Links
IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
Date:11/2/2007

ch 2006.

Updated one-year survival in patients treated with IDM-2101 was 60 percent, compared to 49 percent in a group of seventy-two patients who were HLA-A2 negative but otherwise comparable (external comparator group). Median survival for patients treated with IDM-2101 was 17.3 months compared to 12.0 months for patients in the comparator group. Ninety-one percent of patients treated with IDM-2101, who were tested for immune response, had a measurable response to at least one of the epitopes included in the vaccine with 64 percent responding to at least three of the epitopes. Toxicities attributable to the vaccine were mild and consisted primarily of injection site reactions.

"We are very encouraged by the continued positive survival trend and safety results of IDM-2101 in this study and are eager to continue development of this novel treatment," said Timothy P. Walbert, president and chief executive officer, IDM Pharma, Inc. "We will move forward with our plan to use the final results from this trial, which we expect next year, as a basis in determining an appropriate clinical pathway for IDM-2101."

About IDM-2101

IDM-2101 includes nine CTL epitopes from four tumor associated antigens (TAA) including two proprietary native epitopes and seven modified, or analog, epitopes and one universal epitope a source of T-cell help. Tolerance to TAA, which is a failure of the immune system to recognize the cancer as diseased tissue, is broken by using these analog epitopes which enhance the potency of the T cell response. The Phase 2 IDM-2101 study has been ongoing since late 2004 and the last patient is expected to be treated in May 2008.

About Lung Cancer

Lung cancer continues to be a major health problem with a very high mortality rate and represents the leading cause of cancer death in the United States. According to the American Cancer Society, approximately 213,000 new lung cancer cases will be diagnosed in the United States in 2007
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 Cooperative ... military surgical research and top-tier universities for ... to severe wound treatments for critical-care patients ... medicine and tissue-engineered skin substitute advancements.  Biotech ... in focus are Amarantus Bioscience Holdings, Inc. ...
(Date:8/3/2015)... 2015  BioElectronics Corporation (OTC Pink: BIEL), maker of ... Andrew J. Whelan , President will be interviewed ... Business" at 9am EDT on Wednesday, August 5 th ... http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ Mr. ... the company,s flagship product, ActiPatch Therapy, is achieving in ...
(Date:8/3/2015)... , Aug. 3, 2015  Charleston Laboratories, ... of its second clinical development program with a ... CL-H1T.  CL-H1T contains fast-dissolving promethazine ... developed as a treatment for migraine headache pain ... "Many patients with migraine headaches also suffer ...
Breaking Medicine Technology:Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2
... Md., Nov. 28, 2011 PharmAthene, Inc. (NYSE Amex: ... countermeasures against biological and chemical threats, announced today that ... present at the Piper Jaffray 23rd Annual Healthcare Conference ... Richman will also be available to participate in one-on-one ...
... Conn., Nov. 28, 2011 Gaylord Sleep Medicine now ... their Glastonbury, Guilford, North Haven and Trumbull locations. ... new Sleep Apnea Management program has expanded to offer ... patient needs. Originally designed to improve PAP compliance, the ...
Cached Medicine Technology:PharmAthene to Present at the Piper Jaffray 23rd Annual Healthcare Conference on November 30, 2011 2Gaylord Sleep Medicine Expands Sleep Apnea Management Program 2
(Date:8/4/2015)... ... August 04, 2015 , ... ... Text results have been impressive so far". , Mr Cauchois attributes the ... Winscribe's French sales partner Dicma and the healthcare technology offered by Winscribe's platform. ...
(Date:8/3/2015)... ... 2015 , ... While the pace of the economic recovery since the 2008 has been subject ... growth trajectory for the last six years. Unemployment has dropped from a 2009 high of ... percent growth rate in 2014, the U.S. stock market is at an all time high, ...
(Date:8/3/2015)... ... August 03, 2015 , ... Zeiter’s Septic ... As a family owned and operated business, Zeiter’s Septic has been serving the ... leader in septic installations because of their continued training and perseverance to provide ...
(Date:8/3/2015)... ... 2015 , ... Code , an industry leader of image-based barcode reading ... Reader accessory that enables a wireless connection between the CR5000 and a ... of barcode reading applications with iPads, Galaxy Tabs, and many other products that lack ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay ... claims in which a claimant alleged to have suffered an arterial blood clot including ... control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. In ...
Breaking Medicine News(10 mins):Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 2Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 4Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 2Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 3Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 4Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 2Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 3Health News:Code Launches the T500, an Innovative Code Reader Accessory 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 3Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2
... 10 "The Senate compromise version of H.R. 1, ... no relief to the thousands of state and local ... economic downturn - including those who work in laboratories," ... Public Health Laboratories. "Unfortunately, the Senate has decided that ...
... Inc. (NYSE: NTY ) ( www.NBTY.com ), a leading global manufacturer and marketer of nutritional supplements, today announced the following preliminary unaudited ... NET SALES, ... FOR THE ... ($In Millions), ...
... Potential sale increases focus on growing core businessesCHICAGO, Feb. ... that it has reached an agreement in principle, subject ... to sell its Medication Services business. Closing of the ... conditions, but no assurances can be given that a ...
... as HPV tweak their DNA to escape detection, study ... of cancer-related viruses may actually change to disguise themselves from ... international team of scientists studied the entire genomes of three ... hepatitis B. Each of these pathogens can progress into cancer ...
... even if you stop taking the drug, study finds , , ... aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to reduce ... cancer. , That,s the conclusion of a new study of ... clear, and arguably proven, that NSAID drugs do interfere with ...
... of the Center for Research on Minority Health ... Member for NPAF and PAF, Honored for His ... Feb. 10 The National Patient Advocate Foundation ... that a member of the Foundations, Executive Boards, ...
Cached Medicine News:Health News:Laid Off Public Health Workers Excluded From Senate Stimulus, Governmental Health Laboratories Slammed by Recession 2Health News:NBTY Announces Preliminary Unaudited Net Sales Results for January 2009 2Health News:NBTY Announces Preliminary Unaudited Net Sales Results for January 2009 3Health News:Allscripts Announces Agreement in Principle to Sell Its Medication Services Business 2Health News:Allscripts Announces Agreement in Principle to Sell Its Medication Services Business 3Health News:Genes Help Cancer-Linked Viruses Elude Immune System 2Health News:Long-Term Aspirin Use Seems to Protect Against Colorectal Lesions 2Health News:Long-Term Aspirin Use Seems to Protect Against Colorectal Lesions 3Health News:Executive Board Member of National Patient Advocate Foundation, Patient Advocate Foundation Receives National Institutes of Health 2008 Health Disparities Excellence Award 2Health News:Executive Board Member of National Patient Advocate Foundation, Patient Advocate Foundation Receives National Institutes of Health 2008 Health Disparities Excellence Award 3
Replacement bulb for Vibratome light system....
The V-Block adapter is designed to allow round posts to be placed in the Vibratome vice....
This is a perfect tool for retrieving free floating sections from the Vibratome bath....
... includes everything from the care package ... Spare Fluorescent Bulb, additional Vibratome Feather ... and a Specimen Tray. ... 1/2" speciment mounts, replacement rotating mounts, ...
Medicine Products: